View in EDS

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
Authors: Yopp A; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: adam.yopp@UTSouthwestern.edu., Chen M; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangdong Province, China., Cheng AL; Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Kaseb A; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Lee HC; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Cha E; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Hack SP; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Lian Q; Biostatistics, Genentech Inc, South San Francisco, CA, USA., Spahn J; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA., Wu C; Portfolio Clinical Safety, Roche (China) Holding Ltd, Shanghai, China., Qin S; Department of Medical Oncology, Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China., Chow PK; Division of HPB and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore and Surgery Academic Clinical Programme, Duke-NUS Medical School Singapore, Singapore.
Source: Journal of hepatology [J Hepatol] 2026 Jun; Vol. 84 (6), pp. 1102-1111. Date of Electronic Publication: 2026 Jan 22.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8503886 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0641 (Electronic) Linking ISSN: 01688278 NLM ISO Abbreviation: J Hepatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41580093
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Yopp+A%22">Yopp A</searchLink>; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: adam.yopp@UTSouthwestern.edu.<br /><searchLink fieldCode="AU" term="%22Chen+M%22">Chen M</searchLink>; Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangdong Province, China.<br /><searchLink fieldCode="AU" term="%22Cheng+AL%22">Cheng AL</searchLink>; Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kaseb+A%22">Kaseb A</searchLink>; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kudo+M%22">Kudo M</searchLink>; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+HC%22">Lee HC</searchLink>; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Cha+E%22">Cha E</searchLink>; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lian+Q%22">Lian Q</searchLink>; Biostatistics, Genentech Inc, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Spahn+J%22">Spahn J</searchLink>; Product Development Oncology, Genentech Inc, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Portfolio Clinical Safety, Roche (China) Holding Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Department of Medical Oncology, Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Chow+PK%22">Chow PK</searchLink>; Division of HPB and Transplant Surgery, National Cancer Centre Singapore and Singapore General Hospital, Singapore and Surgery Academic Clinical Programme, Duke-NUS Medical School Singapore, Singapore.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228503886%22">Journal of hepatology</searchLink> [J Hepatol] 2026 Jun; Vol. 84 (6), pp. 1102-1111. <i>Date of Electronic Publication: </i>2026 Jan 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8503886 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1600-0641 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201688278%22">01688278 </searchLink><i>NLM ISO Abbreviation: </i>J Hepatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41580093
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jhep.2026.01.006
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1102
    Titles:
      – TitleFull: Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yopp A
      – PersonEntity:
          Name:
            NameFull: Chen M
      – PersonEntity:
          Name:
            NameFull: Cheng AL
      – PersonEntity:
          Name:
            NameFull: Kaseb A
      – PersonEntity:
          Name:
            NameFull: Kudo M
      – PersonEntity:
          Name:
            NameFull: Lee HC
      – PersonEntity:
          Name:
            NameFull: Cha E
      – PersonEntity:
          Name:
            NameFull: Hack SP
      – PersonEntity:
          Name:
            NameFull: Lian Q
      – PersonEntity:
          Name:
            NameFull: Spahn J
      – PersonEntity:
          Name:
            NameFull: Wu C
      – PersonEntity:
          Name:
            NameFull: Qin S
      – PersonEntity:
          Name:
            NameFull: Chow PK
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2026 Jun
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1600-0641
          Numbering:
            – Type: volume
              Value: 84
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Journal of hepatology
              Type: main
ResultId 1